03 April 2019 : Original article
Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Cheng-ying Zhu12BCDEFG, Sha-sha Zhao2B, Xiao-kai Wang3BCE, Li Wang4BC, Fei-yan Wang1CD, Shu Fang2EF, Zhan-xiang Liu2B, Li-xun Guan2D, Yu-chen Liu2D, Yi Ding2E, Li-ping Dou2D, Li-li Wang2D, Chun-ji Gao12FG*DOI: 10.12659/AOT.914101
Ann Transplant 2019; 24:175-184
Abstract
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication following solid organ transplantation and allogeneic hematopoietic stem cell transplantation (Allo-HSCT), which gives rise to high mortality rates.
MATERIAL AND METHODS: This was a single-center retrospective analysis based on 27 patients who were diagnosed with PTLD following Allo-HSCT between January 1, 2007 and June 2018 at the Chinese PLA General Hospital. The purpose of this analysis was to investigate responses and prognostic factors of rituximab-based treatment.
RESULTS: Twenty-seven patients were treated with rituximab. Among them, 20 of 27 patients (74.07%) had a complete response, 2 of 27 patients (7.41%) had a partial response, 5 of 27 patients (18.52%) had no response, and 22 of 27 patients (81.48%) cleared Epstein-Barr virus (EBV) copies. There were no obvious side effects. The 1-year overall survival (OS) estimate was 46.8% (95% CI, 23.1–65.5%). Univariate analysis revealed that lower OS was correlated with Eastern Cooperative Oncology Group (ECOG) score standard (3–4), Epstein-Barr virus (EBV) viral load (≥10⁶ copies/mL), bacteria or fungal infection, and EBV reactivation were positive after treatment with 1 or 2 doses of rituximab (P<0.05). Multivariate analysis showed that each of the following were independently associated with lower OS (P<0.05): female, ECOG score standard (3–4), and EBV reactivation were positive after treatment with 1 or 2 doses of rituximab.
CONCLUSIONS: Our results demonstrated that rituximab-based treatment was a safe and effective strategy for patients who were diagnosed with PTLD following Allo-HSCT. The identified prognostic factors may help to detect which PTLD patients are at a higher risk of mortality.
Keywords: Epstein-Barr Virus Infections, Graft vs Host Disease, Lymphoproliferative Disorders, Transplants, Adolescent, Antineoplastic Agents, Immunological, Child, DNA, Viral, Postoperative Complications, Proportional Hazards Models, rituximab, Time Factors, Transplantation, Homologous, Viral Load, Virus Activation, young adult
In Press
Original article
Effect of Medical Accessibility on Long-Term Survival in Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.944839
Original article
Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-UpAnn Transplant In Press; DOI: 10.12659/AOT.946088
Most Viewed Current Articles
05 Apr 2022 : Original article 13,221
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,677
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,822
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,535
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860